GlassScriptPhysician profile
Saqib Z Syed
NPI 1942436522
$6,983.31
in general payments reported to CMS, 2019-2025
32 companies · $1,247 in 2025
The $1,247 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $411 · 2021: $784 · 2022: $1,053 · 2023: $1,111 · 2024: $1,620 · 2025: $1,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,945 · Education: $33.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,944.53 |
| Education | $33.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $1,020.64 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $670.27 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $612.66 | 2022-2025 | Filspari |
| Amgen INC. | $608.61 | 2022-2025 | Krystexxa, Tavneos, Repatha |
| Aurinia Pharma U.S., INC. | $413.30 | 2022-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $382.33 | 2021-2024 | |
| Horizon Therapeutics Plc | $335.99 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $303.73 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $288.70 | 2021-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $259.32 | 2020-2024 | Benlysta, Jesduvroq |
| Novo Nordisk INC | $244.37 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Corcept Therapeutics | $232.65 | 2025 | Korlym |
| Mallinckrodt Hospital Products INC. | $213.91 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $172.53 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $138.17 | 2022-2025 | Tarpeyo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $137.05 | 2019 | |
| Mallinckrodt Enterprises LLC | $123.51 | 2019 | |
| Ani Pharmaceuticals, INC. | $122.58 | 2022-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $121.78 | 2024 | Mounjaro |
| Baxter Healthcare | $86.34 | 2019 | |
| Vifor Pharma, INC. | $83.10 | 2020-2025 | Veltassa |
| Daiichi Sankyo INC. | $78.97 | 2019-2021 | |
| Nxstage Medical, INC. | $69.45 | 2019 | |
| Cormedix INC. | $51.56 | 2024 | Defencath |
| Shield Therapeutics INC | $48.49 | 2024-2025 | |
| Ardelyx, INC. | $47.61 | 2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.59 | 2024-2025 | Jardiance |
| Imbed Biosciences INC. | $20.25 | 2023 | |
| Pharmacosmos Therapeutics INC. | $18.86 | 2025 | Monoferric |
| Fresenius USA Marketing, INC. | $17.50 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.55 | 2023 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saqib Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.